Intra-arterial thrombectomy: does invasive treatment lead to better outcomes than intravenous thrombolysis alone?
Intravenous thrombolysis is considered to be standard of care for acute ischemic stroke patients arriving within 3-4.5 h of stroke symptom onset. Recently, endovascular therapies have been proposed to extend and enhance stroke outcomes by targeting large vessel occlusions. Different radiologic methods, time windows, and treatment tools have delineated differences between trials. Overall, intravenous thrombolysis remains the treatment of choice for all acute ischemic stroke patients, with a small subset benefiting from additional endovascular therapy. Endovascular therapy remains a viable singular option for patients with large vessel occlusion unable to receive thrombolysis.
Section of Cerebrovascular Disease, Department of Neurology, Rush University Medical Center, 1725 W. Harrison Street, Suite 1121, Chicago, IL, 60612, USA, Laurel_J_Cherian@rush.edu.
Laurel
L
Cherian
Shawna
S
Cutting
Sarah
S
Song
D002545:Brain Ischemia / Q000503:physiopathology / Q000628:therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D020521:Stroke / Q000517:prevention & control / Q000628:therapy*; D017131:Thrombectomy; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D016896:Treatment Outcome
D010959:Tissue Plasminogen Activator